Payment overview · 2025
General Payments
$141.00
2 reported records · 2 companies
Healthcare provider profile · identity verified
Veronica Cadena, MD
Allopathic & Osteopathic Physicians|Family Medicine · DEL RIO, TX · NPI 1255335592
Verified facts
What the public records show
CMS Open Payments records show Veronica Cadena, MD received $141.00 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 57.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.84 | 57.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.16 | 42.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.84 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $60.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 766 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 686 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 151 |
| Metformin Hcl | Metformin Hcl | 451 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 129 |
| Lisinopril | Lisinopril | 365 | 119 |
| Losartan Potassium | Losartan Potassium | 342 | 96 |
| Montelukast Sodium | Montelukast Sodium | 294 | 73 |
| Sertraline Hcl | Sertraline Hcl | 283 | 65 |
| Gabapentin | Gabapentin | 225 | 58 |
| Glimepiride | Glimepiride | 209 | 49 |
| Omeprazole | Omeprazole | 208 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 59 |
| Alprazolam | Alprazolam | 195 | 67 |
| Alendronate Sodium | Alendronate Sodium | 191 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 47 |
| Simvastatin | Simvastatin | 178 | 56 |
| Furosemide | Furosemide | 160 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 51 |
| Tramadol Hcl | Tramadol Hcl | 145 | 37 |
| Ozempic | Semaglutide | 139 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 32 |
| Trazodone Hcl | Trazodone Hcl | 109 | 39 |
| Potassium Chloride | Potassium Chloride | 104 | 35 |
| Donepezil Hcl | Donepezil Hcl | 100 | 26 |
| Januvia | Sitagliptin Phosphate | 99 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 28 |
| Carvedilol | Carvedilol | 95 | 33 |
| Meloxicam | Meloxicam | 95 | 26 |
| Eliquis | Apixaban | 91 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 22 |
| Famotidine | Famotidine | 82 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 52 |
| Meclizine Hcl | Meclizine Hcl | 80 | 28 |
| Memantine Hcl | Memantine Hcl | 80 | 21 |
| Finasteride | Finasteride | 79 | 26 |
| Jardiance | Empagliflozin | 79 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 76 | 22 |
| Allopurinol | Allopurinol | 75 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 28 |
| Cephalexin | Cephalexin | 71 | 39 |
| Telmisartan | Telmisartan | 66 | 13 |
| Ezetimibe | Ezetimibe | 65 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 22 |
| Lorazepam | Lorazepam | 59 | 17 |
| Glipizide | Glipizide | 58 | 17 |
| Enalapril Maleate | Enalapril Maleate | 57 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Clonazepam | Clonazepam | 49 | 16 |
| Metformin Hcl Er | Metformin Hcl | 49 | 13 |
| Atenolol | Atenolol | 48 | 12 |
| Fenofibrate | Fenofibrate,micronized | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 23 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Naproxen | Naproxen | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 11 |
| Pregabalin | Pregabalin | 29 | 12 |
| Levetiracetam | Levetiracetam | 28 | 11 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Ibuprofen | Ibuprofen | 24 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Linzess | Linaclotide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Constulose | Lactulose | 14 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Euthyrox | Levothyroxine Sodium | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Evista | Raloxifene Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.00 · 2 records | Novo Nordisk Inc | Ozempic, Repatha | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error